The DOI matches its Crossref record; 135 of the 136 references it cites were found in a registry or an index.
Self-amplifying RNA vaccines for infectious diseases
Open accessAbstract
Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, which are then formulated for delivery. This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages of synthetic manufacturing approaches, and their potential for preventing and treating chronic infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“saRNAs use an RNA-dependent RNA polymerase from an alphavirus and the corresponding conserved sequence elements at the 5′ and 3′ ends for replication, leading to robust and durable expression of encoded protein cargo5–7.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Similar to other mRNA vaccine platforms, saRNA facilitates rapid candidate design and development, as well as cell-free molecule synthesis.152”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [152]
In the citing paper
“The virus-derived polymerase amplifies mRNA transcripts intracellularly, enabling the expression of large amounts of antigen with reduced mRNA doses9.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla‐Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,810
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,478
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077
Reversible methylation of m6Am in the 5′ cap controls mRNA stability
Mauer, J., Luo, X., Blanjoie, A., Jiao, X., Grozhik, A. V., Patil, D. P., Linder, B., Pickering, B. F., Vasseur, J., Chen, Q., et al. (2016) · Nature · doi:10.1038/nature21022 · Cited by 1,072
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members
Daffis, S., Szretter, K. J., Schriewer, J. M., Li, J., Youn, S., Errett, J. S., Lin, T., Schneller, S. W., Züst, R., Dong, H., et al. (2010) · Nature · doi:10.1038/nature09489 · Cited by 910
Research works printed but not linked: 1
- Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003;77:10394–403. · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 488
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 38
Meany, E. L., Klich, J. H., Jons, C. K., Mao, T., Chaudhary, N., Utz, A., Baillet, J., Song, Y. E., Saouaf, O. M., Ou, B. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2631 · Cited by 37
Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
Ferreira, R. G., Gordon, N. F., Stock, R., & Petrides, D. P. (2021) · Processes · doi:10.3390/pr9081430 · Cited by 36
Glycosylation as a key parameter in the design of nucleic acid vaccines
Ozdilek, A., & Avci, F. Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102348 · Cited by 34
Advances and prospects of mRNA vaccines in cancer immunotherapy
Liu, Y., Yan, Q., Zeng, Z., Fan, C., & Xiong, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189068 · Cited by 33
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 33
Zeng, L., Li, D., Tong, W., Shi, T., & Ning, B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114424 · Cited by 32
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Pfeifer, B. A., Beitelshees, M., Hill, A. B., Bassett, J., & Jones, C. H. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00323-3 · Cited by 33
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
RNA Nanomedicine: Delivery Strategies and Applications
Byun, J., Wu, Y., Park, J.-W., Kim, J. S., Li, Q., Choi, J., Shin, N., Lan, M., Cai, Y., Lee, J., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00860-z · Cited by 32
Lombaerde, E. D., Cui, X., Chen, Y., Zhong, Z., Deckers, J., Mencarelli, G., Opsomer, L., Wang, H., Baere, J. D., Lienenklaus, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09677 · Cited by 31
Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses
Liu, Y., Li, Y., & Hu, Q. (2023) · Vaccines · doi:10.3390/vaccines11071142 · Cited by 27
Schmidt, C., Haefner, E. S., Gerbeth, J., Beißert, T., Şahin, U., Perković, M., & Schnierle, B. S. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.036 · Cited by 28
Feng, S., Rcheulishvili, N., Jiang, X., Zhu, P., Pan, X., Wei, M., Wang, P. G., Ji, Y., & Papukashvili, D. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.87741 · Cited by 27
Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies
Ulrichs, T., Rolland, M., Wu, J., Nunes, M. C., Guerche‐Séblain, C. E., & Chit, A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2346589 · Cited by 25
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations
Omidi, Y., Pourseif, M. M., Ansari, R. A., & Barar, J. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2419815 · Cited by 29
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
“There are two main types of mRNA technologies: conventional mRNA and self-amplifying mRNA (saRNA) (reviewed in (5)).”
BackgroundSelf-citationJoshi, G., Borah, P., Thakur, S., Sharma, P., Mayank, M., & Ramarao, P. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1995283 · Cited by 28
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 26
COVID-19 Vaccines: An Updated Overview of Different Platforms
Kudlay, D. A., Svistunov, A. А., & Сатышев, О. В. (2022) · Bioengineering · doi:10.3390/bioengineering9110714 · Cited by 25
RNA Therapeutics: A Healthcare Paradigm Shift
Niazi, S. K. (2023) · Biomedicines · doi:10.3390/biomedicines11051275 · Cited by 25
Tissue-resident memory T cells in protective immunity to influenza virus
Lee, S., Yeung, K., & Watts, T. H. (2024) · Current Opinion in Virology · doi:10.1016/j.coviro.2024.101397 · Cited by 24
Azizi, H., Renner, T. M., Agbayani, G., Simard, B., Dudani, R., Harrison, B. A., Iqbal, U., Jia, Y., McCluskie, M. J., & Akache, B. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae004 · Cited by 28
Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
Anthony, D. P. S., Sivakumar, K., Venugopal, P., Sriram, D. K., & George, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01022-9 · Cited by 23
Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]
Jawalagatti, V., Kirthika, P., & Lee, J. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884862 · Cited by 24
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
de Mey, W., Esprit, A., Thielemans, K., Breckpot, K., & Franceschini, L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3304 · Cited by 27
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection
Krähling, V., Erbar, S., Kupke, A., Nogueira, S. S., Walzer, K. C., Berger, H., Dietzel, E., Halwe, S., Rohde, C., Sauerhering, L., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.011 · Cited by 24
Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine
Abdellatif, A. A. H., Younis, M. A., Alsowinea, A. F., Abdallah, E. M., Abdel‐Bakky, M. S., Al-Subaiyel, A., Hassan, Y. A., & Tawfeek, H. M. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113111 · Cited by 24
The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles
Johnson, M. M., Jones, C. E., & Clark, D. N. (2022) · Viruses · doi:10.3390/v15010107 · Cited by 29
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Cancer mRNA vaccines: clinical application progress and challenges
Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 26
Advancements in RNA-based therapies from bench to bedside
Singh, A., Tekade, M., Nagaraja, S., Bharti, A., & Tekade, R. K. (2026) · npj Drug Discovery. · doi:10.1038/s44386-025-00037-y · Cited by 24
The mRNA vaccine, a swift warhead against a moving infectious disease target
Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 28
Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine
Komori, M., Morey, A. L., Quiñones-Molina, A. A., Fofana, J., Romero, L., Peters, E., Matsuda, K., Gummuluru, S., Smith, J. F., Akahata, W., et al. (2023) · doi:10.1101/2023.11.01.565056 · Cited by 21
Peletta, A., Lemoine, C., Courant, T., Collin, N., & Borchard, G. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106699 · Cited by 21
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 24
Advancements and challenges in next-generation mRNA vaccine manufacturing systems
Seo, S. H., & Song, M. (2025) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2025.14.e40 · Cited by 21
mRNA Vaccine - A New Cancer Treatment Strategy
Tan, T., Deng, S., Wu, B.-H., Yang, Q., Wu, M., Wu, H., Cao, C., & Xu, C. S. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230222124424 · Cited by 22
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
mRNA Vaccine Platform: mRNA Production and Delivery
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020152 · Cited by 26
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sheikhlary, S., Lopez, D. H., Moghimi, S., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14040503 · Cited by 22
Hick, T. A. H., Geertsema, C., Nguyen, W., Bishop, C., van Oosten, L., Abbo, S. R., Dumenil, T. D., van Kuppeveld, F. J. M., Langereis, M. A., Rawle, D. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.019 · Cited by 21
Trends in the synthetic polymer delivery of RNA
Friesen, J. J., & Blakney, A. K. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3672 · Cited by 22
Unlocking the Potential of Chemically Modified Nucleic Acid Therapeutics
Gao, J., Nutan, B., Gargouri, D., Pisal, N. D., Do, V., Zubair, M., Alanzi, H., Wang, H., Lee, D., Joshi, N., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400231 · Cited by 20
Bacteriophage RNA polymerases: catalysts for mRNA vaccines and therapeutics
Nair, A., & Kis, Z. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1504876 · Cited by 20
RNA stability enhancers for durable base-modified mRNA therapeutics
Jung, S.-J., Seo, J. J., Lee, S., Hyun, S.-I., Lee, J.-E., Lee, S., Lee, Y., Chang, H., Lee, H., Kim, J.-H., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02891-7 · Cited by 26
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 21
A complex network-based vaccination strategy for infectious diseases
Sun, L., He, Q., Teng, Y., Zhao, Q., Yan, X., & Wang, X. (2023) · Applied Soft Computing · doi:10.1016/j.asoc.2023.110081 · Cited by 20
Charge neutralized poly(β-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA
Dastgerdi, N. K., Gümüş, N., Bayraktutan, H., Jackson, D., Polra, K., McKay, P. F., Atyabi, F., Dinarvand, R., Shattock, R. J., Martínez‐Pomares, L., et al. (2024) · Nanoscale Advances · doi:10.1039/d3na00794d · Cited by 20
Single-molecule RNA sizing enables quantitative analysis of alternative transcription termination
Patiño‐Guillén, G., Pešović, J., Panić, M., Pavicevic, D. S., Bošković, F., & Keyser, U. F. (2024) · Nature Communications · doi:10.1038/s41467-024-45968-8 · Cited by 20
Vosoughi, P., Naghib, S. M., Kangarshahi, B. M., & Mozafari, M. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139532 · Cited by 23
Elliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 21
Low, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2021) · doi:10.1101/2021.07.01.21259831 · Cited by 19
RNA-based vaccines and innate immune activation: Not too hot and not too cold
Frederickson, R., & Herzog, R. W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.005 · Cited by 19
Mahony, T. J., Briody, T. E., & Ommeh, S. C. (2024) · Vaccines · doi:10.3390/vaccines12020152 · Cited by 22
Casmil, I. C., Bathula, N. V., Huang, C., Wayne, C. J., Cairns, E. S., Friesen, J. J., Soriano, S. K. V., Liao, S., Ho, C., Kong, K. Y. S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.055 · Cited by 18
Opsomer, L., Jana, S., Mertens, I., Cui, X., Hoogenboom, R., & Sanders, N. N. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb03003b · Cited by 18
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041173 · Cited by 17
Self-citationRemoval of dsRNA byproducts using affinity chromatography
Clark, N. E., Kozarski, M., Asci, S. D., den Heuvel, J. V., Schraut, M. R., Winters, R. A., Kearns, K., Scanlon, T. C., & Dillen, S. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102549 · Cited by 17
Gamboa, L., Zamat, A. H., Thiveaud, C., Lee, H. J., Kulaksizoglu, E., Zha, Z., Campbell, N., Chan, C. S., Fábrega, S., Oliver, S. A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00968-5 · Cited by 25
Innovative gene engineering strategies to address tumor antigen escape in cell therapy
Chen, Y., Niu, S., Li, Y.-R., & Yang, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07259-8 · Cited by 19
From high-throughput to therapeutic: host-directed interventions against influenza viruses
Trimarco, J. D., & Heaton, N. S. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.12.014 · Cited by 17
Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2
Mohamed, N. A., Abou-Saleh, H., Mohamed, H. A., Al-Ghouti, M. A., Crovella, S., & Zupin, L. (2022) · Viruses · doi:10.3390/v14071553 · Cited by 17
Karan, S., Duran-Meza, A. L., Chapman, A., Tanimoto, C. R., Chan, S. K., Knobler, C. M., Gelbart, W. M., & Steinmetz, N. F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01105 · Cited by 19
COVID-19 Variants and Vaccine Development
Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 20
Tadic, S., & Martı́nez, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433185 · Cited by 19
Vijukumar, A., Kumar, A., & Kumar, H. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116699 · Cited by 17
Self-replicating vehicles based on negative strand RNA viruses
Lundstrom, K. H. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00436-7 · Cited by 16
Akhter, S., Berchel, M., Jaffrès, P., Midoux, P., & Pichon, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030581 · Cited by 20
Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910136 · Cited by 15
Coatsome-replicon vehicles: Self-replicating RNA vaccines against infectious diseases
Démoulins, T., Schulze, K., Ebensen, T., Techakriengkrai, N., Nedumpun, T., Englezou, P. C., Gerber, M., Hlushchuk, R., Toledo, D., Djonov, V., et al. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102655 · Cited by 16
Mohanty, P., Panda, P., Acharya, R. K., Pande, B., Bhaskar, L. V., & Verma, H. K. (2023) · World Journal of Virology · doi:10.5501/wjv.v12.i5.242 · Cited by 17
An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection
Safarchi, A., Fatima, S., Ayati, Z., & Vafaee, F. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00674-6 · Cited by 16
Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
Tregoning, J. S., Wang, Z., Sridhar, S., Shattock, R. J., & DeRosa, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.011 · Cited by 21
Self-immolative polyplexes for DNA delivery
Sirianni, Q. E. A., Wang, T., Borecki, A., Deng, Z., Ronald, J. A., & Gillies, E. R. (2022) · Biomaterials Science · doi:10.1039/d1bm01684a · Cited by 17
Domínguez, F. D. B. P., Palchevska, O., Frolova, E. I., & Frolov, I. V. (2023) · Journal of Virology · doi:10.1128/jvi.01225-23 · Cited by 15
Tapescu, I., Madsen, P. J., Lowenstein, P. R., Castro, M. G., Bagley, S. J., Fan, Y., & Brem, S. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454370 · Cited by 16
Advances in RNA therapeutics: Classes, innovations and clinical applications
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100016 · Cited by 18
Compact polyethylenimine-complexed mRNA vaccines
Herrero, J. M., Stahl, T. B., Erbar, S., Maxeiner, K., Schlegel, A., Bacic, T., Schumacher, J., Cavalcanti, L. P., Schroer, M. A., Svergun, D. I., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01961-w · Cited by 16
Paul-Chima, U. O., Okon, M. B., Ogenyi Fabian, C., Nnenna, U. J., & Ugwu, C. N. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2661120 · Cited by 18
Speeckaert, R., Lambert, J., Puig, L., Speeckaert, M. M., Lapeere, H., Schepper, S. D., & van Geel, N. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00349-0 · Cited by 14
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Poly(2-oxazoline)/saRNA Polyplexes for Targeted and Nonviral Gene Delivery
Hayes, G., Barbieri, B. D., Yilmaz, G., Shattock, R. J., & Becer, C. R. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00683 · Cited by 14
Cheung, M., Chang, C. W., Rathnasinghe, R., Rossignol, E. D., Zhang, Y.-F., Ferrari, A., Patel, H., Huang, Y., Guillen, M. A. S., Scalzo, T., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00747-2 · Cited by 14
Araste, F., Bakker, A. D., & Zandieh‐Doulabi, B. (2023) · Journal of Nanoparticle Research · doi:10.1007/s11051-023-05867-3 · Cited by 15
mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option
Niazi, S. K., & Magoola, M. (2023) · Biologics · doi:10.3390/biologics3040020 · Cited by 13
Transforming drug development with synthetic biology and AI
Hill, A. B., True, J. M., & Jones, C. H. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.01.008 · Cited by 14
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
del Moral-Sánchez, I., Wee, E. G., Xian, Y., Lee, W.-H., Allen, J. D., Torrents de la Peña, A., Fróes Rocha, R., Ferguson, J., León, A. N., Koekkoek, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00862-8 · Cited by 14
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections
Zhuang, Z., Zhuo, J., Yuan, Y., Chen, Z., Zhang, S., Zhu, A., Zhao, J., & Zhao, J. (2024) · Vaccines · doi:10.3390/vaccines12050478 · Cited by 14
Ho, N. T., Hughes, S. G., Sekulovich, R. E., Ta, V. T., Nguyễn, T. V., Pham, A. T. V., Lương, Q. C., Tran, L. T. L., Luu, A. T. V., Nguyen, A. N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01017-5 · Cited by 14
Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2
Lin, G., Yan, H., Sun, J., Zhao, J., & Zhang, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.021 · Cited by 14
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms
Ahn, W., Lee, Y., Nam, G., You, J. B., & Lee, E. J. (2025) · Small Science · doi:10.1002/smsc.202500270 · Cited by 15
Yu, P., Dan, M., He, Y., Meng, S., Yang, H.-Y., Su, X., Wang, Y., Lv, L., Sun, Y., Tao, X., et al. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106425 · Cited by 13
Development of mRNA rabies vaccines
Fang, Z., Yu, P., & Zhu, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2382499 · Cited by 16
1mΨ influences the performance of various positive-stranded RNA virus-based replicons
Miyazato, P., Noguchi, T., Ogawa, F., Sugimoto, T., Fauzyah, Y., Sasaki, R., & Ebina, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-68617-y · Cited by 13
mRNA vaccines against HIV : Hopes and challenges
Zubair, A., Ahmad, H., Arif, M. M., & Ali, M. (2025) · HIV Medicine · doi:10.1111/hiv.70024 · Cited by 14
Metadata
- Authors
- Bloom, K., van den Berg, F., & Arbuthnot, P.
- Affiliations
- South African Medical Research Council (ZA)
- Corresponding author
- Bloom, Kristie
- Venue
- Gene Therapy
- Published
- 2020-10-22
- Volume
- 28
- Issue
- 3-4
- Pages
- 117-129
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC7580817
- OpenAlex
- W3093949211
- Cited by
- 487
- References
- 136
- Citations by year
- 2026: 68 · 2025: 107 · 2024: 98 · 2023: 80 · 2022: 71 · 2021: 61 · 2020: 2
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gene Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- South African Medical Research Council
- National Research Foundation (118022, 120383)
- Poliomyelitis Research Foundation (18/01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- self-amplifying RNA vaccine, RNA vaccines, infectious disease vaccines, in vitro transcription, SARS-CoV-2, influenza, respiratory syncytial virus, rabies, Ebola, HIV-1, chronic infection
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, RNA, Viral, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
